Phase 2 Safety, Tolerability and Efficacy Study of CPI-613 in Cancer Patients
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Cancer
Interventions: DRUG: CPI-613
Sponsor: Cornerstone Pharmaceuticals